Payment overview · 2025
General Payments
$183.59
2 reported records · 2 companies
Healthcare provider profile · identity verified
Publius Martins, MD
Allopathic & Osteopathic Physicians|Internal Medicine · STATEN ISLAND, NY · NPI 1821073917
Verified facts
What the public records show
CMS Open Payments records show Publius Martins, MD received $183.59 in general payments during 2025 across 2 reported records.
Abbott Laboratories accounted for 86.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $158.79 | 86.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.80 | 13.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $183.59 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $158.79 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
102 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 411 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 400 | 107 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 390 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 367 | 88 |
| Metformin Hcl | Metformin Hcl | 336 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 325 | 109 |
| Azithromycin | Azithromycin | 271 | 128 |
| Pantoprazole Sodium | Pantoprazole Sodium | 242 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 241 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 64 |
| Losartan Potassium | Losartan Potassium | 218 | 62 |
| Lisinopril | Lisinopril | 193 | 53 |
| Simvastatin | Simvastatin | 190 | 54 |
| Breo Ellipta | Fluticasone/Vilanterol | 187 | 43 |
| Alprazolam | Alprazolam | 143 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 32 |
| Furosemide | Furosemide | 139 | 39 |
| Prednisone | Prednisone | 136 | 41 |
| Omeprazole | Omeprazole | 130 | 35 |
| Montelukast Sodium | Montelukast Sodium | 129 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 127 | 39 |
| Allopurinol | Allopurinol | 123 | 37 |
| Famotidine | Famotidine | 121 | 33 |
| Ozempic | Semaglutide | 113 | 24 |
| Gabapentin | Gabapentin | 110 | 27 |
| Synthroid | Levothyroxine Sodium | 102 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 23 |
| Atenolol | Atenolol | 88 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 27 |
| Glimepiride | Glimepiride | 78 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 23 |
| Jardiance | Empagliflozin | 76 | 18 |
| Eliquis | Apixaban | 74 | 18 |
| Valsartan | Valsartan | 73 | 22 |
| Nifedipine Er | Nifedipine | 67 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 26 |
| Torsemide | Torsemide | 65 | 14 |
| Azelastine Hcl | Azelastine Hcl | 55 | 20 |
| Bupropion Xl | Bupropion Hcl | 53 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 52 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 50 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 48 | suppressed |
| Diazepam | Diazepam | 48 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 20 |
| Naproxen | Naproxen | 46 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 12 |
| Trazodone Hcl | Trazodone Hcl | 44 | suppressed |
| Meloxicam | Meloxicam | 43 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | 11 |
| Enalapril Maleate | Enalapril Maleate | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 11 |
| Lorazepam | Lorazepam | 37 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 13 |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Lactulose | Lactulose | 34 | suppressed |
| Cefdinir | Cefdinir | 33 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | 12 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 11 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 19 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Podofilox | Podofilox | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $183.59 · 2 records | Abbott Laboratories | NAVITOR, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error